Login to Your Account



Competing Offer Not Likely, Given Price

Merck Picks Best Horse' In $1.1B Sirna Buyout: Analyst

By Randall Osborne


Wednesday, November 1, 2006
Merck & Co. Inc.'s plan to buy Sirna Therapeutics Inc. for $1.1 billion, despite two of Sirna's major programs tied to partnerships with other pharma firms, casts a shadow over the Merck deal with Alnylam Pharmaceuticals Inc., rival of Sirna in the RNA interference space. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription